Jubilant Pharmova Limited's board of directors, at its meeting held on October 12, 2026, approved the issuance of Secured/Unsecured, Listed, Rated, Redeemable Non-Convertible Debentures (NCDs) on a private placement basis, according to a filing made with the National Stock Exchange. The announcement signals the company's intent to raise debt capital through the NCD route, a mechanism commonly used by listed corporates to diversify their borrowing mix outside traditional bank credit.

NCD Issuance: Key Details

The board has cleared the issuance of NCDs that will be listed on a recognised stock exchange. The debentures are structured as redeemable instruments, meaning principal repayment is guaranteed at maturity, with interest payable as per the terms of each tranche. The private placement route restricts the offer to a select set of institutional and sophisticated investors, as permitted under SEBI's debt securities regulations. Specific quantum, coupon rate, tenor, and allotment date have not been disclosed in the exchange filing and are expected to be communicated upon finalisation of the placement.

Dividend History: Five Consecutive Years of ₹5 Per Share

Separately, Jubilant Pharmova's dividend track record reveals a consistent but flat payout pattern over the past several years. The company has recommended a final dividend of ₹5 per equity share every year from FY2021 through FY2026, as confirmed by successive NSE filings dated June 2021, May 2022, May 2023, May 2024, May 2025, and most recently May 2026. This represents five consecutive years of an unchanged payout at the ₹5 level.

Dividend Trend Analysis

The dividend per share grew from ₹3 in FY2017 and FY2018 to ₹4.50 in FY2019, before stepping up to ₹5 in FY2020 and remaining locked at that level for six consecutive payout cycles through FY2026. While the company has maintained consistency in honouring shareholder payouts without any cut, the absence of incremental growth in the dividend quantum over this extended period indicates that the board has not enhanced the absolute cash return to equity shareholders despite the passage of time. The face value of the equity share is Re. 1 per share, making the ₹5 payout equivalent to a 500% dividend on face value.

What This Means for Investors

Since current market price data and trade information were not available in the exchange disclosures at the time of this report, a precise dividend yield calculation cannot be provided. Investors should compute yield as ₹5 divided by the prevailing market price of JUBLPHARMA to assess income return. The NCD issuance, once sized and priced, will provide clarity on the company's near-term debt cost and capital allocation priorities. Investors tracking the stock should note that the combination of a flat dividend trajectory and a fresh debt-raising exercise warrants monitoring of the company's balance sheet leverage and interest coverage metrics in forthcoming quarterly results.